CAMS for Suicidality: Collaborative Assessment and Treatment

Author: Angela Bogdanova · Published: October 18, 2026 · Editorial Policy

Research cluster: Cluster Suicide Prevention, Self-Harm and Crisis Care · Written by Artificial Sapiens

Collaborative Assessment and Management of Suicidality (CAMS) is a structured, suicide-focused clinical framework developed by psychologist David A. Jobes. It brings a patient and a trained clinician into a sustained collaboration to understand the individual's suicidal experience, identify the problems and experiences that drive it, create a stabilization plan, and evaluate meaningful change over the course of treatment. The Suicide Status Form (SSF) supports this work through repeated assessment, collaborative formulation, treatment planning, and documentation. CAMS can organize elements of psychotherapy and clinical management; its actual effectiveness depends on patient population, comparator care, implementation fidelity, and the outcome being measured. VA/DoD Clinical Practice Guideline, 2024; Swift, Trusty, and Penix, 2021.

The central scientific finding is specific. Comparative research suggests that CAMS can reduce suicidal ideation and improve some patient-reported outcomes, while evidence that it prevents suicide attempts, repeated self-harm, or suicide deaths remains substantially less certain. A 2021 meta-analysis found a small average comparative benefit for suicidal ideation, but the 2024 VA/DoD guideline concluded that the available evidence was insufficient to recommend either for or against CAMS to reduce suicidal ideation. Those assessments apply different evidentiary standards and emphasize different limitations; neither establishes that CAMS is universally superior to other competent suicide-focused care. Swift et al., 2021; VA Rocky Mountain MIRECC recommendation, 2024.

What CAMS means and what it is designed to treat

Collaborative Assessment and Management of Suicidality

The name identifies three connected clinical tasks. Assessment creates a detailed, shared account of the patient's suicidal thoughts, circumstances, and reasons for living and dying. Management addresses current safety, access to support, and the choices required when danger increases. Treatment works on the patient's own identified suicidal drivers over successive sessions. Collaboration means the patient's perspective is an active source of clinical knowledge and treatment decisions, while the clinician retains responsibility for professional judgment, safeguarding, and timely escalation when needed.

CAMS treats suicidality as an explicit clinical concern, rather than assuming that improvements in a psychiatric diagnosis will automatically resolve suicidal thoughts. A patient may experience depression, trauma-related distress, substance use, relationship rupture, isolation, financial precarity, or persistent shame; their suicidal crisis may be shaped by several of these interacting processes. Addressing a depressive syndrome, for example, remains important, yet CAMS additionally asks what currently makes suicide appear to the person as a possible answer and what would make continued living more attainable. This orientation is articulated in the VA/DoD CAMS clinical resource and in descriptions of the Suicide Status Form.

A framework rather than a psychiatric diagnosis

CAMS is a treatment framework. It is not a diagnosis, a standalone screening instrument, or a formula that predicts who will die by suicide. It also is not simply an empathetic conversation or a single completed safety-plan worksheet. It organizes repeated clinical contacts around a documented, negotiated understanding of suicide-specific suffering and movement toward stabilization. The patient's mental health diagnoses and medical conditions are assessed and treated alongside the suicide-focused work.

How CAMS developed

Jobes developed CAMS from work on collaborative, patient-centered assessment of suicidality, with the SSF becoming its organizing clinical document. Its theoretical lineage includes research on psychological pain, hopelessness, agitation, attachment and the working alliance, but CAMS is a pragmatic clinical framework that accommodates multiple explanatory models and treatment techniques. Historical theories help explain why its questions are asked; a theory's plausibility alone does not validate a treatment's clinical effectiveness. Contemporary CAMS research includes community outpatient, college counseling, military, inpatient, and post-hospital studies, each with different selection criteria and comparators. Jobes et al., 2017; Pistorello et al., 2021; Santel et al., 2023.

Essential clinical definitions

Suicidal ideation, intent, and suicidal behavior

Suicidal ideation refers to thoughts about death or suicide, but thoughts differ in frequency, intensity, meaning, imagery, perceived controllability, and relationship to intention. Passive suicidal ideation includes wishing to be dead or not to wake up without necessarily considering an action to end one's life. Active suicidal ideation includes thoughts of taking one's own life; it does not by itself establish an intention to act. Suicidal intent concerns a person's current desire or determination to perform an action with the purpose of dying. A suicide attempt is a nonfatal, potentially injurious act accompanied by at least some intent to die. Clinical assessment explores ambiguity, changing intent, and what happened before, during, and after any behavior. VA/DoD guideline, 2024.

Self-harm and nonsuicidal self-injury

Nonsuicidal self-injury (NSSI) involves deliberate injury without intent to die, although intent may be mixed, uncertain, or change. Some health systems, particularly those using the broad language of NICE NG225, define self-harm as intentional self-poisoning or injury irrespective of apparent purpose. Suicidal self-injury and NSSI may coexist over time; prior self-harm is a marker of future clinical concern, but the category of a single act must be determined through assessment rather than appearance. CAMS specifically focuses on suicidal suffering while comprehensive care considers all self-injurious behaviors and their functions. NICE NG225; Witt et al., 2021.

Acute crisis, persistent ideation, and clinical change

An acute suicidal crisis refers to an escalation of distress and potentially dangerous intent or behavior requiring timely assessment and possibly emergency intervention. Chronic suicidal ideation describes recurring or enduring thoughts over longer periods; it may remain distressing, intensify acutely, or fluctuate with circumstances. Chronicity cannot be equated with safety. CAMS is especially interested in tracking an individual's changing suicidal experience rather than treating an earlier label or score as a permanent state.

Risk factors, warning signs, and immediate clinical danger

Risk factors are characteristics statistically associated with suicide-related outcomes across populations, such as a previous attempt, certain psychiatric conditions, isolation, or exposure to violence. Warning signs are changes suggesting the need for prompt attention, including recent expressed intent, escalating agitation, marked withdrawal, or new inability to remain safe. Immediate clinical danger depends on what is happening now, including current intent, access to potentially lethal means, recent actions, intoxication, judgment, available support, and the person's ability to engage in urgent care. These concepts inform care but do not become accurate individualized forecasts simply by being scored. NICE NG225; WHO suicide fact sheet, 2026.

Why a suicide-focused collaborative approach may matter

Psychological pain and perceived entrapment

People describing suicidal experiences often report intolerable internal pain, a sense of being trapped, exhaustion, perceived burdensomeness, or loss of hope. These are important clinical experiences, though their causal role varies among individuals and no single psychological model explains every suicidal crisis. CAMS invites the person to define which experiences feel intolerable and under what conditions they become linked to suicidal thinking. The clinical aim is to build a formulation with observable targets rather than to impose a universal causal story.

The working alliance as a clinical process

The therapeutic alliance involves agreement on goals and tasks alongside a relationship in which the patient can disclose difficult material. CAMS makes that agreement explicit: the clinician and patient examine the SSF together and decide which suicidal drivers and protective resources need attention. Greater alliance may improve engagement, openness, and retention, but its mediating causal role in CAMS remains under investigation. A secondary analysis of randomized data explored differential effects by alliance characteristics and should be interpreted as exploratory rather than proof that one alliance variable explains treatment success. Ryberg et al., 2020.

Reasons for living and ambivalence

A suicidal person may simultaneously experience a desire for relief from suffering and attachments, values, responsibilities, relationships, hopes, or beliefs favoring continued life. CAMS discusses reasons for living and reasons for dying in a collaborative, individualized way. The purpose is to understand what matters to the patient and make changes that can support continued safety; it is not to shame the person or pressure them into affirming that life is satisfactory. A patient's willingness to describe ambivalence is meaningful clinical information, and support must remain available even if hope is temporarily hard to articulate.

Social and environmental conditions

Housing instability, discrimination, violence, inaccessible treatment, family conflict, unemployment, medical illness, and social disconnection can shape suicidal crises. Some drivers require practical advocacy and coordinated services as much as individual psychotherapy. Environmental safety, assistance accessing medical care, financial and housing services, and involvement of trusted people may be important components of a wider treatment plan. WHO LIVE LIFE framework; WHO suicide fact sheet, 2026.

The Suicide Status Form: How collaborative assessment works

Why the SSF is central

The Suicide Status Form is a structured clinical instrument and documentation process used with the patient, not merely a questionnaire administered separately from treatment. It gathers subjective descriptions and ratings of suicide-related experiences, summarizes history and clinical concerns, supports decisions about stabilization, specifies treatment targets, and permits repeated reviews of progress. Clinician judgment and direct conversation contextualize the numbers throughout. The developer's SSF overview describes an initial assessment, interim tracking, and outcome or disposition phases.

Domains assessed over time

The SSF commonly asks patients to rate psychological pain, stress, agitation, hopelessness, and self-hate. It also explores reasons for living and dying and the patient's appraisal of risk. These domains guide clinical questioning: what has changed, what the numbers mean to this person, and how specific developments link to suicidal thoughts. Repeated ratings can reveal patterns worth discussing, but a score is neither a diagnostic classification nor a clinically reliable estimate of the probability of suicide. Santel et al. study protocol, 2020.

Initial clinical conversation and shared formulation

A competent first CAMS assessment involves listening to the person's account, clarifying suicidal thoughts and behavior, reviewing the past and present context, and negotiating a statement of the main suicidal drivers. Clinical history includes previous attempts, self-harm, psychiatric and medical conditions, substance use, medications, trauma, recent losses, protective relationships, and access to treatment. A person may initially find disclosure difficult because of stigma, fear of hospitalization, cultural differences, or previous negative experiences in care. The clinician should explain confidentiality and its safety-related limits in clear language and invite correction of the formulation.

Stabilization planning as part of treatment

The CAMS stabilization plan is a practical, individualized strategy for responding when suicidal distress increases. It can include personal warning signs, ways to reduce distress, contact with trusted supporters, access to urgent professional care, and collaborative steps to reduce access to dangerous items or situations during heightened risk. A stabilization plan is reviewed and revised as circumstances change. It does not replace medical evaluation, active crisis response, or care for coexisting psychiatric and physical conditions. Related work on safety planning has its own intervention literature and should not be treated as an interchangeable proof of CAMS effectiveness. VA/DoD guideline, 2024; NICE NG225.

Ongoing sessions and disposition

At subsequent meetings, the patient and clinician revisit the SSF, examine developments since the prior contact, test the treatment plan against lived experience, and address the identified drivers. Resolution and disposition depend on sustained clinical improvement and a safe, coordinated plan for what follows. The standard model describes a structured process for ending the CAMS episode after sustained reduced suicidality, including assessment across consecutive contacts; such procedural criteria guide care but do not establish a guarantee of future safety. Relapse-prevention planning, continued care for underlying conditions, and rapid re-entry to services remain relevant. SSF clinical overview.

Screening, assessment, diagnosis, and risk formulation

Screening determines who needs a fuller conversation

Suicide screening instruments can help clinicians recognize that further assessment is required. A positive result is an invitation to timely clinical evaluation. A negative result does not invalidate expressed distress or override concerning current behavior. The choice of screening approach depends on age, setting, population, language, and local procedures. CAMS itself requires a therapeutic assessment process and should not be described as equivalent to a brief screen.

Psychosocial assessment is individualized

A comprehensive assessment considers suicidal intent, recent behavior, current safety, psychiatric symptoms, physical illness, developmental stage, practical stressors, protective supports, cultural context, and the person's preferences and goals. It examines both immediate needs and continuing support. NICE NG225 requires a psychosocial assessment and advises professionals to perform a risk formulation describing the circumstances and processes relevant to safety and care. A sound formulation can explicitly describe uncertainty and specify what developments would change the immediate management plan. NICE recommendations.

Why risk scales cannot determine treatment access

NICE specifically advises against using risk scales to predict future suicide or repeated self-harm, to decide access to treatment or discharge, or to assign low-, medium-, and high-risk bands for those purposes. SSF scores can organize collaborative discussion and show within-person change, but their existence does not bypass these principles. Clinical decisions also depend on an examination of acute safety, medical needs, environmental conditions, available services, and professional responsibility. NICE NG225, section 1.6.

Diagnosis and comorbidity

CAMS can be used in the presence of depressive disorders, bipolar disorder, personality dysfunction, trauma-related disorders, substance use disorders, psychotic disorders, or neurodevelopmental differences. The clinician must evaluate these conditions according to relevant diagnostic criteria, and treatment is adapted to them. For example, an acutely manic, intoxicated, delirious, or psychotic patient may require immediate medical or psychiatric stabilization before a conventional collaborative outpatient session is feasible. An intrusive unwanted self-harm thought in obsessive-compulsive disorder may call for a different formulation from suicidal intent; a psychiatric assessment explores its meaning rather than inferring intent from its wording alone.

How a CAMS treatment episode is organized

Referral, eligibility, and informed consent

Referral may follow primary-care detection, a psychiatric assessment, hospital discharge, or a presentation to a counseling clinic. A clinician establishes whether the person can participate in collaborative treatment at that point, whether emergency care is required, and how CAMS fits the current treatment system. The rationale, expected meetings, measurement, confidentiality, and alternative options are discussed. Where service availability is limited, the priority is access to appropriate suicide-specific care and continuity, whether or not a trained CAMS clinician is accessible.

Translating suicidal drivers into clinical goals

A broad problem such as "my life is falling apart" may contain several actionable components: unmanageable panic, ongoing abuse, severe insomnia, unaddressed grief, persistent conflict, or an inability to reach medical support. The patient and clinician clarify which of these most directly intensify suicidal thoughts, how they interact, and which services or skills could change the situation. Goals can involve treatment for a mood disorder, emotion-regulation training, trauma-informed care, practical crisis resolution, or restoration of trusted social connection. Goals are reviewed against the patient's own ratings and descriptions rather than completed as administrative checkboxes.

Integrating other evidence-based treatments

CAMS can provide a suicide-focused organizing structure while the clinician uses skills or treatments supported for the person's other conditions. This requires clarity about what is being delivered: incorporating a cognitive or behavioral technique in CAMS does not mean that a trial of full cognitive behavioral therapy has been replicated. Similarly, referring a patient to comprehensive dialectical behavior therapy (DBT) is different from offering a few DBT-inspired skills. Medicines can treat indicated coexisting conditions under appropriate medical supervision, while medication outcomes should not be attributed automatically to CAMS. Clear descriptions of combined care are essential for reproducible research and honest patient communication.

Documentation and interdisciplinary coordination

Shared records should capture the patient's account, immediate and longer-term concerns, negotiated drivers, safety actions, relevant changes, and referrals. With consent and appropriate privacy protections, outpatient clinicians, emergency services, inpatient teams, primary care, and family supports can coordinate responsibilities. The quality of handoffs matters, particularly when appointments, medication access, and emergency plans change. CAMS documentation should assist communication and clinical reasoning rather than produce an impression of mathematical risk certainty.

What clinical trials and meta-analyses actually show

Why outcome definitions come first

Suicidal ideation can be measured by rating scales and repeated self-report, whereas suicide attempts and self-harm episodes require distinct definitions and ascertainment. Suicide deaths are rare relative to changes in symptom ratings and demand considerably larger samples and longer observation periods for intervention studies. Improvement in hope, overall distress, or treatment satisfaction may benefit patients, but none of these measures can be substituted for evidence of fewer deaths. Studies may use treatment as usual, enhanced care, or another active therapy as the comparator, and these differences change what an effect estimate means.

The nine-study meta-analysis of CAMS

Swift, Trusty, and Penix synthesized nine comparative empirical studies in a 2021 random-effects meta-analysis. Against alternative interventions, CAMS showed a small average advantage for suicidal ideation (Cohen's d = 0.25) and general distress (d = 0.29), higher treatment acceptability (d = 0.42), and a larger estimate for hope or hopelessness outcomes (d = 0.88). The included trials did not show statistically significant between-group advantages for suicide attempts, self-harm, or cost-effectiveness. Moderator analyses suggested smaller ideation advantages in active-duty military or veteran samples and among male participants. As with any meta-analysis of a relatively small and heterogeneous trial literature, publication bias, differences in control treatment, fidelity, follow-up, and outcome measures constrain generalization. Swift et al., 2021.

The VA/DoD 2024 evidence judgment

The 2024 VA/DoD clinical practice guideline reviewed research on CAMS and reached a conclusion of insufficient evidence to recommend for or against its use to reduce suicidal ideation. Its working group noted low confidence in the evidence and the inclusion of studies that modified the protocol. The recommendation recognizes that potential benefit must be weighed against burden, alternatives, patient preference, and local resources. This guideline assessment is an important counterweight to descriptions that label CAMS unconditionally effective or the single preferred treatment for everyone. VA/DoD guideline landing page; MIRECC recommendation 8.

U.S. Army outpatient randomized trial

The Operation Worth Living randomized trial compared CAMS with enhanced care as usual in 148 U.S. Army soldiers presenting to an outpatient behavioral health clinic with significant suicidal ideation. At three months, CAMS participants were less likely to report any suicidal thoughts than participants receiving enhanced care, while the groups did not show consistent differences across the other prespecified outcomes or later observation points. Both groups improved during care. The result supports a possible short-term, outcome-specific effect rather than a general conclusion that CAMS prevents attempts or deaths in military populations. The study's population, intensity of enhanced care, retention, and military service context matter for applicability. Jobes et al., 2017.

College counseling randomized trial

A randomized feasibility study assigned 62 suicidal college students to CAMS or treatment as usual in a university counseling setting. Both groups improved. CAMS showed greater change in depression and suicidal ideation on measures obtained during treatment, while exploratory moderation suggested that clinical characteristics such as borderline personality features and previous attempts may influence comparative response. Small samples and subgroup comparisons are especially prone to unstable estimates. The finding is relevant to college-age outpatient treatment but should not be generalized to every student or interpreted as an adolescent efficacy trial. Pistorello et al., 2021.

Post-hospital next-day appointment trial

A randomized trial evaluated a next-day appointment model using CAMS after a suicide-related hospitalization. The 150 participants had histories of actual, aborted, or interrupted suicide attempts and received CAMS or treatment as usual. Both groups improved over follow-up, and CAMS was not superior to usual treatment on the primary outcomes. Differences at selected time points favored different groups for different suicidal-ideation metrics. The study supports feasibility of rapid postdischarge engagement but does not establish CAMS superiority in this transitional-care population. Reducing short term suicide risk after hospitalization, 2022.

Acute psychiatric inpatient feasibility trial

Santel and colleagues randomized 88 acutely suicidal psychiatric inpatients to CAMS or enhanced treatment as usual. Intention-to-treat analyses showed improvement in both arms without significant between-group differences on the main longitudinal outcomes of ideation, depression, distress, or reasons for living. Some treatment-completer analyses and secondary outcomes, including alliance ratings and a short postdischarge attempt comparison, favored CAMS. Completer results can be affected by differential retention and must not replace randomized intention-to-treat findings. This small feasibility study is promising for inpatient adaptation but cannot establish reliable prevention of postdischarge attempts. Santel et al., 2023.

Interpret the studies together

Evidence should be evaluated as a portfolio rather than as a vote count of favorable trials. The randomized studies encompass different health systems, clinician training arrangements, acuity levels, treatment duration, and comparator quality. Many samples were too small to estimate effects on uncommon behavioral outcomes with useful precision. Symptom scales and follow-up schedules also varied. CAMS appears a reasonable suicide-focused clinical option in settings capable of providing trained, responsive care, but patient-specific selection should incorporate clinical need and preferences without asserting unique efficacy that existing evidence cannot demonstrate. Swift et al., 2021; VA/DoD, 2024.

CAMS compared with other suicide-focused interventions

CAMS and dialectical behavior therapy

Comprehensive DBT is a multicomponent treatment that typically includes individual psychotherapy, skills training, between-session coaching, and therapist consultation. It may be particularly relevant when suicidal and self-harming behaviors occur alongside recurrent emotion dysregulation and complex interpersonal difficulties. CAMS instead uses repeated collaborative assessment and suicide-driver-focused treatment planning as its organizing framework. Direct comparisons and indirect cross-trial impressions must account for differences in patient selection, treatment intensity, and measured outcomes. A review advocating use of both frameworks provides useful clinical interpretation, but author involvement with either model should be visible when weighing conclusions. Jobes and Rizvi, 2024; Witt et al., 2021.

CAMS and cognitive behavioral therapy for suicide prevention

Suicide-focused cognitive behavioral interventions may formulate links among beliefs, intense affect, coping strategies, behavior, and safety. Some programs explicitly address relapse prevention, problem solving, and rehearsal of responses to future crises. CAMS may incorporate cognitive or behavioral techniques when they address patient-defined suicidal drivers, but an individualized CAMS episode is not equivalent to a complete standardized course of suicide-focused CBT. Evidence for one intervention cannot be transferred to another because both use collaborative goal setting or written plans. The 2024 VA/DoD guideline separately appraises psychotherapy approaches and their outcome evidence. VA/DoD, 2024.

CAMS and the Safety Planning Intervention

The Stanley-Brown Safety Planning Intervention is a distinct brief, collaborative process that produces a prioritized plan for recognizing crises, using coping responses, accessing people and professional help, and enhancing environmental safety. CAMS includes a stabilization plan as one component of an ongoing suicide-focused treatment framework. Their overlapping language reflects compatible clinical objectives but different intervention packages, research designs, and typical delivery settings. Evidence from an emergency-department safety-planning-and-follow-up intervention does not demonstrate that CAMS reduces attempts, and CAMS psychotherapy studies do not establish the effectiveness of a standalone safety-plan worksheet.

CAMS and postdischarge contact interventions

Caring contacts, telephone follow-up, emergency-department discharge planning, and rapid outpatient appointments aim to improve continuity during vulnerable transitions. They can supplement but do not replace an indicated course of psychotherapy. Studies of such programs often measure new care contacts, repeat emergency visits, attempts, and ongoing treatment attendance. CAMS may be incorporated into a continuity model, but any composite program must specify which components were delivered and which causal inferences are supported. NICE NG225; Reducing short term suicide risk, 2022.

CAMS alongside diagnosis-directed care

If a person has bipolar disorder, psychosis, severe depression, a substance use disorder, trauma-related symptoms, or significant chronic pain, effective care must address those conditions directly. Some presentations require psychiatric medication review, medical workup, management of intoxication or withdrawal, sleep stabilization, social work, safeguarding, or inpatient treatment. A CAMS clinician's suicide-focused formulation can complement these services but cannot replace them. Clinical appropriateness should be decided by the responsible treatment team and adjusted as needs evolve.

Adolescents, young adults, and developmental context

CAMS for teenagers is an adaptation with a developing evidence base

CAMS for Teens has been described in preliminary clinical research involving adolescents, including work on feasibility, acceptability, and adaptation to developmental needs. Such studies contribute to intervention design but cannot be treated as definitive randomized evidence of fewer adolescent suicide attempts or deaths. Adolescent presentations involve developmental differences in autonomy, emotion regulation, family relationships, school context, confidentiality, and access to treatment. The Adrian et al. CAMS for Teens report documents a promising approach and explicitly motivates further rigorous evaluation.

Family involvement and safeguarding

In adolescent care, collaboration commonly needs to include parents or caregivers in carefully negotiated ways, while preserving space for the young person to discuss sensitive thoughts and experiences. Clinicians explain confidentiality and legal safeguarding duties, evaluate abuse or unsafe environments, and determine what information must be shared to protect the young person's safety. A family member should learn relevant warning signs, how to support follow-through with treatment, and how to obtain urgent help. When family participation would increase danger, clinicians must identify other safe and lawful support pathways. The adolescent's agreement and voice remain central whenever developmentally and clinically possible.

School and community coordination

Schools may assist with referral, safety at school, attendance adjustments, and coordination with caregivers or youth mental health services. The treatment plan should avoid converting ordinary educational personnel into clinical risk assessors. Privacy protections, permission to share information, and a named responsible clinician are essential. Peer support can reduce isolation while urgent clinical risk remains the responsibility of professionals and emergency systems.

Evidence from college students does not equal evidence from teenagers

The college counseling randomized study concerns students in a particular university outpatient setting; it must be assessed separately from CAMS for Teens and from research on adolescents admitted for acute psychiatric care. Trial participants can differ by age, legal consent, prior attempts, family participation, service access, and baseline severity. A treatment adaptation remains preliminary until adequately powered studies evaluate its own target population and meaningful clinical endpoints. Pistorello et al., 2021; Adrian et al., 2021.

Clinical populations that require specific adaptations

Patients with previous attempts or repeated self-harm

Previous suicidal behavior and recurrent self-harm require careful discussion of circumstances, intent, functions of behavior, previous care, and changing supports. For some patients, severe self-harm may occur without an expressed wish to die, while others describe mixed or fluctuating motives. Treatment should address the functions of repeated behaviors and immediate safety, using other indicated interventions when necessary. Trials enrolling only participants with substantial attempt histories may not reproduce findings from outpatient ideation studies. The postdischarge trial illustrates the importance of this distinction. Postdischarge CAMS trial, 2022; NICE NG225.

Personality dysfunction and intense emotion dysregulation

For a person experiencing recurrent crises, relational instability, extreme shame, or emotion dysregulation, the clinician should consider whether comprehensive DBT, other structured treatments, or coordinated multidisciplinary services are indicated. CAMS can help formulate suicidal drivers and support engagement, but the presence of suicidal ideation alone does not establish that CAMS can replace a full treatment program for complex personality pathology. Trial subgroup findings are exploratory and should not be transformed into categorical exclusions from care. Pistorello et al., 2021.

Psychosis, mania, intoxication, and impaired capacity

When reality testing, judgment, attention, or capacity for informed participation is acutely compromised, the immediate clinical priority is appropriate emergency assessment and management. The standard collaborative session may need to be delayed, modified, or integrated into inpatient care after stabilization. Psychotic symptoms, intoxication, or mania do not erase the person's preferences, but clinicians must evaluate capacity and clinical danger in the actual situation. Do not infer an absence of risk from a calm presentation or a single denial of intent.

Trauma, abuse, grief, and social disadvantage

Suicidal drivers may include traumatic reminders, ongoing victimization, bereavement, discrimination, poverty, or a lack of safe housing. Trauma-informed practice helps clinicians avoid coercive communication and attend to what makes disclosure possible. Practical action, referral, advocacy, and coordinated safeguarding may be necessary alongside therapeutic work. A diagnosis-neutral treatment framework should not obscure structural sources of distress. WHO emphasizes that effective suicide prevention extends beyond one-to-one psychotherapy to community, environmental, and public-health responses. WHO suicide fact sheet, 2026.

Autistic people and accessibility

Collaborative treatment should be made accessible to individual communication preferences, sensory needs, language processing, and social context. A patient may prefer written questions, predictable session agendas, clearer definitions of emotional states, or more time to describe distress. Autistic people can face distinctive sources of stress and barriers to being understood in health care; these must be assessed rather than assumed. Evidence directly validating standard CAMS outcomes in autistic subgroups remains limited, so adaptations should be documented and evaluated. Clinical concerns relating to autistic adults have their own evidence base and separate canonical research focus.

Veterans and service members

Military service and veteran care may involve moral injury, chronic pain, transition stress, exposure histories, service eligibility, and specialized care systems. Outcomes in military trials cannot be treated as interchangeable with those in general outpatient clinics. The CAMS soldier trial showed a limited short-term ideation advantage but no consistent overall superiority, while the VA/DoD guideline explicitly judged the broader evidence insufficient. Treatment preferences, burden of attendance, clinician training, continuity, and local veteran services matter. Jobes et al., 2017; VA/DoD, 2024.

What a responsible CAMS service needs

Competent clinicians and crisis response capacity

CAMS should be delivered by professionals working within their scope of practice who have adequate suicide-assessment competencies, access to supervision or consultation, and an established route for urgent escalation. Training in the model's SSF process and fidelity principles helps distinguish full CAMS from informal use of its terminology. An outpatient clinic needs a plan for what happens when a patient cannot maintain immediate safety, misses a critical visit, or loses access to prescribed care. A research-backed intervention cannot compensate for an unsafe organizational system.

Treatment setting and referral pathways

A college counseling center, veteran clinic, psychiatric ward, and community outpatient practice operate under different rules. Each requires appropriate staffing, appointment availability, consent procedures, records management, urgent medical referral pathways, and arrangements for continuing care. Care transitions deserve special attention because a patient may move from acute stabilization into environments where previous stressors rapidly return. Rapid contact after discharge is valuable as a systems objective, but the superiority of a particular branded treatment has to be demonstrated in the population receiving it. Post-hospital CAMS trial, 2022; NICE NG225.

Fidelity, adaptation, and treatment contamination

Research protocols often assess whether clinicians actually used the SSF collaboratively, defined suicidal drivers, completed stabilization planning, and reviewed progress as intended. Modified CAMS, a partial implementation, and usual care that includes similar collaboration may produce different effect sizes. Studies should disclose training, adherence checks, supervision, departures from protocol, and concurrent therapy. The VA/DoD guideline specifically identified modifications to CAMS as part of its uncertainty about efficacy. VA/DoD CAMS recommendation.

Patient dignity, confidentiality, and shared responsibility

Meaningful collaboration depends on the person's understanding that disclosure will be treated respectfully, that emergency actions have explained clinical grounds, and that preferences matter. Clinicians must also convey the boundaries of confidentiality and respond to acute danger even when the preferred form of participation is temporarily impossible. Safety-related decisions should be documented with contextual reasoning, clear roles, and a plan for follow-up. Patients have a right to understandable information about CAMS, its alternative treatments, and the uncertainty around behavioral and mortality outcomes.

Measurement-based improvement without mechanical prediction

Repeated self-report measures can help an individual notice changes that might otherwise be hard to describe and help a clinical service understand who is disengaging. That use is different from labeling a person as safe because scores improved. Health services should evaluate patient-centered outcomes, completed follow-up, access disparities, adverse experiences, and behavior-related endpoints when studies are sufficiently powered. Reports should transparently distinguish treatment response, retention, and service utilization from suicide mortality. NICE NG225.

When immediate emergency care is needed

If someone has current intent to act on suicidal thoughts, has recently made an attempt, cannot remain safe, or appears at imminent risk because of severe confusion, intoxication, or rapidly escalating behavior, urgent emergency assessment is necessary. Stay with the person when it is safe to do so, contact local emergency services, and help limit access to dangerous items without putting anyone at risk. Do not wait for a scheduled CAMS appointment or rely on a previously completed SSF when circumstances have changed.

In the United States, call 911 for an immediate life-threatening emergency. Call or text 988 to reach the Suicide and Crisis Lifeline for crisis support; 988 is a U.S. service and should not be presented as an international number. People outside the United States should use their local emergency number and locally verified crisis services. If danger is not immediate but suicidal thoughts are present, arranging timely contact with a qualified clinician, a trusted support person, or an existing treatment team can begin a fuller assessment. CDC suicide resources; 988 Suicide and Crisis Lifeline.

What patients can ask a clinician

A person considering CAMS can ask what the framework involves, how the SSF will be used, what happens when a crisis intensifies between sessions, how competing treatment options are considered, and whether the clinician is trained in suicide-focused therapy. It is reasonable to ask how existing diagnoses, medication treatment, family supports, practical difficulties, and cultural or communication preferences will be integrated. The clinician should explain how progress and treatment changes will be discussed, not promise that any single therapy eliminates future risk.

What family members and supporters can do

Supporters can listen calmly, ask directly about suicidal thoughts when concerned, take threats or changing behavior seriously, and help the person connect with professional care. They can participate in a safety or stabilization plan when the patient agrees and when their involvement is safe. They should know which service to contact for urgent help and avoid acting as an unsupervised substitute for emergency or specialist care. For adolescents, professionals must address caregiver participation and safeguarding according to developmental and legal context.

Population prevention and where CAMS fits

CAMS operates at the clinical treatment level: it is intended for individuals whose suicide-related distress requires professional care. At the population level, prevention also involves safer environments, responsible reporting, youth life-skills programs, early identification, access to responsive services, and reductions in social and structural barriers to care. WHO's LIVE LIFE framework provides a multilevel approach. An individual psychotherapy trial cannot show that a national prevention strategy reduces suicide deaths, and a population policy evaluation does not establish CAMS treatment effects. The levels complement one another when service systems are designed to connect people with continuing support. WHO suicide prevention; CDC public-health strategy.

Why suicide mortality data require care

Suicide is a major cause of preventable death globally. WHO estimated 727,000 suicide deaths in 2021, while noting limitations in the quality of national death registration and comparability of estimates. These figures establish public-health urgency; they do not estimate how many deaths CAMS prevents. Mortality outcomes require direct outcome measurement and transparent evaluation designs. WHO, Suicide worldwide in 2021, 2025; WHO mortality data quality.

Limitations, scientific disputes, and future research

What counts as convincing evidence

A well-designed randomized trial must define the clinical population, comparator, adherence to treatment, follow-up schedule, preselected primary outcomes, missing-data methods, and adverse outcomes. A small difference in a repeated symptom rating may be important yet should be interpreted alongside its uncertainty interval and actual clinical consequences. The absence of statistical significance for attempts is not proof of equivalence; many existing CAMS studies lack sufficient events to identify a meaningful difference. Likewise, a favorable association in treatment completers cannot outweigh a nonsignificant randomized primary analysis.

Independent replication and researcher involvement

Several influential CAMS studies include clinicians or researchers involved in developing or disseminating the model. That involvement does not invalidate findings, but it makes independent replication, disclosed financial interests, blinded outcome assessment where feasible, and preregistered analyses important. Treatment preference and clinician allegiance can influence subjective outcomes, retention, and differences between comparison groups. Reviews should scrutinize trial conduct and reporting rather than treating the number of publications as a direct measure of evidence strength.

Which components produce improvement?

The SSF, repeated symptom tracking, explicit focus on suicidal drivers, joint formulation, stabilization planning, treatment engagement, and ordinary supportive contact may all contribute to outcomes. At present, component-specific causal effects are incompletely established. A dismantling or factorial study could help clarify whether a particular CAMS element adds benefit beyond high-quality care and which components are necessary for different patients. Process measures should distinguish the patient's perception of alliance from a demonstrable mechanism of clinical change.

Longer follow-up and meaningful behavioral outcomes

Much published research emphasizes ideation and distress during or near treatment. Larger pragmatic studies need standardized measures of attempts, repeated self-harm, emergency care, sustained quality of life, disability, engagement, and adverse consequences, alongside adequate follow-up. Suicide mortality would require exceptionally large, carefully designed evidence programs. Implementation research should examine rural and under-resourced settings, service interruptions, equitable access, cultural adaptation, and the opportunity costs of specialized training.

Digital care and artificial intelligence

A digital SSF platform or secure telehealth delivery system can support documentation and communication, but clinical efficacy depends on the treatment actually delivered and the services available when danger increases. Automated symptom monitoring, algorithmic triage, general-purpose chatbots, AI companions, and clinician-delivered CAMS via video are distinct interventions with distinct risks and evidence requirements. An automated system must not infer individual suicide probability from a score and cannot be assumed to deliver CAMS merely because it asks about pain or hopelessness. Evidence about a trained clinician's collaborative treatment does not validate unsupervised AI crisis care.

A balanced evidence judgment

The strongest defensible overall conclusion is that CAMS is a clearly articulated, patient-collaborative, suicide-focused framework with evidence of modest benefits for suicidal ideation in some comparisons, meaningful implementation and acceptability data, and unresolved uncertainty about effects on suicide attempts, recurrent self-harm, and mortality. The VA/DoD guideline's insufficient-evidence recommendation remains an important clinical appraisal. A patient should receive responsive, individualized, professionally competent care rather than be made to wait for access to one named approach. Swift et al., 2021; VA/DoD recommendation 8, 2024.

Frequently asked questions about CAMS

Is CAMS a type of psychotherapy?

CAMS is a clinical framework for collaborative assessment, management, and treatment of suicidality. It can structure psychotherapy sessions while allowing individualized therapeutic techniques and coordination with other care. Describing the intervention accurately requires identifying the SSF-centered process and the treatment actually delivered.

How is CAMS different from ordinary suicide risk assessment?

A risk assessment gathers information for clinical decisions, while CAMS uses ongoing collaborative assessment as part of an active treatment relationship. The same form supports a shared formulation, stabilization, work on suicidal drivers, and review of progress. A one-time screening result or completed questionnaire does not constitute a course of CAMS.

Does CAMS prevent suicide attempts or suicide deaths?

Comparative evidence is considerably stronger for changes in suicidal ideation than for attempts, repeated self-harm, or mortality. The 2021 CAMS meta-analysis did not find significant advantages for attempts or self-harm in the included studies, and individual trials have important sample-size and design limitations. A reduction in symptom ratings must never be re-described as proof of prevented deaths. Swift et al., 2021.

What does the SSF measure?

The form asks about subjective states such as psychological pain, stress, agitation, hopelessness, and self-hate, together with suicide-related circumstances and reasons for living or dying. It supports repeated collaboration and documentation. Its ratings are clinically contextual information, not a reliable numerical forecast of an individual's future behavior.

Can CAMS be used with medication or other therapy?

Yes, when indicated and coordinated by qualified professionals. CAMS may help organize suicide-focused work while separate treatment addresses depression, bipolar disorder, substance use, trauma, psychosis, or medical conditions. Clinicians should specify which treatments are delivered and why.

Is CAMS suitable for adolescents?

Adolescent adaptations exist, but their empirical support remains developing. The evidence in adult or college populations cannot be assumed to establish adolescent effectiveness. Youth care requires developmental assessment, safeguarding, appropriate caregiver involvement, and access to emergency support when needed. Adrian et al., 2021.

How long does CAMS take?

The framework involves repeated meetings and review of suicide-specific progress; treatment length varies with clinical presentation, response, and setting. Formal descriptions use criteria for sustained reduced suicidality and documented disposition. The relevant question is whether the person has an effective and safe continuing care plan, including other treatment when needed, rather than whether a fixed session count has been reached. SSF clinical overview.

What should happen if suicidal intent increases during CAMS?

The clinician should reassess immediate safety and act according to the person's current condition, including emergency assessment when warranted. An established stabilization plan can support urgent steps but is not a substitute for professional intervention. In a life-threatening U.S. emergency call 911; U.S. crisis support is available through 988. Elsewhere use local emergency and crisis services. CDC resources.

Related Articles

Suicide Risk Assessment: Clinical Interview, Context, and Decisions — Clinical formulation and decision-making across changing presentations.

Suicide Safety Planning: How Collaborative Safety Plans Work — Safety planning as a distinct, evidence-informed intervention.

Dialectical Behavior Therapy for Self-Harm and Suicidal Behavior — Comprehensive DBT, clinical populations, and differentiated outcomes.

Suicide Prevention After Hospital Discharge: Risk and Follow-Up — Continuity, vulnerable transitions, and structured postdischarge care.

Self-Harm and Suicide Attempts: Differences, Overlap, and Risk — Classification, intent, and clinical overlap.

Suicide Risk in Autistic Adults: Evidence, Assessment, and Prevention — Population-specific research and clinical accessibility.

Suicidal OCD: Intrusive Self-Harm Thoughts, Compulsions, and the Difference From Suicidal Intent — Distinguishing unwanted intrusive thoughts from suicidal intent.

BPD and Self-Harm: Risk, Safety Planning, and Treatment — Emotion dysregulation, self-harm, and diagnosis-focused care.

References

Adrian, M., Blossom, J. B., Chu, P., Jobes, D. A., and McCauley, E. (2021). Collaborative Assessment and Management of Suicidality for Teens: A promising frontline intervention for addressing adolescent suicidality. Practice Innovations, 7(2), 154–167. https://doi.org/10.1037/pri0000156.

Centers for Disease Control and Prevention. (2026). Suicide prevention resources. https://www.cdc.gov/suicide/resources/.

Centers for Disease Control and Prevention. (2026). Suicide prevention: Public health strategy. https://www.cdc.gov/suicide/php/public-health-strategy/index.html.

Jobes, D. A., et al. (2017). A randomized controlled trial of the Collaborative Assessment and Management of Suicidality versus enhanced care as usual with suicidal soldiers. Psychiatry, 80(4), 339–356. https://doi.org/10.1080/00332747.2017.1354607.

Jobes, D. A., and Rizvi, S. L. (2024). The use of CAMS and DBT to effectively treat patients who are suicidal. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1354430.

National Institute for Health and Care Excellence. (2022). Self-harm: Assessment, management and preventing recurrence (NG225). https://www.nice.org.uk/guidance/ng225/chapter/recommendations.

Pistorello, J., et al. (2021). A randomized controlled trial of the Collaborative Assessment and Management of Suicidality (CAMS) versus treatment as usual (TAU) for suicidal college students. Archives of Suicide Research, 25(4), 765–789. https://doi.org/10.1080/13811118.2020.1749742.

Ryberg, W., Diep, L. M., Landrø, N. I., and Fosse, R. (2020). Effects of the Collaborative Assessment and Management of Suicidality model: A secondary analysis of moderation and influencing factors. Archives of Suicide Research, 24(4), 589–608. https://doi.org/10.1080/13811118.2019.1650143.

Santel, M., et al. (2023). The Collaborative Assessment and Management of Suicidality compared to enhanced treatment as usual for inpatients who are suicidal: A randomized controlled trial. Frontiers in Psychiatry, 14, 1038302. https://doi.org/10.3389/fpsyt.2023.1038302.

Swift, J. K., Trusty, W. T., and Penix, E. A. (2021). The effectiveness of the Collaborative Assessment and Management of Suicidality (CAMS) compared to alternative treatment conditions: A meta-analysis. Suicide and Life-Threatening Behavior, 51(5), 882–896. https://doi.org/10.1111/sltb.12765.

U.S. Department of Veterans Affairs and U.S. Department of Defense. (2024). VA/DoD clinical practice guideline for assessment and management of patients at risk for suicide. https://www.healthquality.va.gov/guidelines/mh/srb/.

U.S. Department of Veterans Affairs, Rocky Mountain MIRECC. (2024). Recommendation 8: Collaborative Assessment and Management of Suicidality (CAMS). https://www.mirecc.va.gov/visn19/cpg/recs/8/.

Witt, K. G., et al. (2021). Psychosocial interventions for self-harm in adults. Cochrane Database of Systematic Reviews, CD013668. https://doi.org/10.1002/14651858.CD013668.pub2.

World Health Organization. (2025). Suicide worldwide in 2021: Global health estimates. https://www.who.int/publications/i/item/9789240110069.

World Health Organization. (2026). Suicide: Fact sheet. https://www.who.int/en/news-room/fact-sheets/detail/suicide.